Product Description
Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100beta protein, responsible for inducing neuronal death. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23514413/)
Mechanisms of Action: S-100β Synthesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Stroke
Phase 2: Ischemic Stroke|Infarction, Middle Cerebral Artery
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00401310 | P2 |
Terminated |
Ischemic Stroke|Infarction, Middle Cerebral Artery |
2009-01-01 |
|
| 2008-002079-28 | P2 |
Terminated |
Ischemic Stroke |
2008-11-06 |
|
| ONO-2506-08 | P3 |
Completed |
Stroke |
2008-09-01 |
|
| 2506/INT0104 | P3 |
Terminated |
Stroke |
2005-05-01 |